Clinical Trials

MediZen was established in 1999 and specialises in aesthetic rejuvenation of the face and body with cosmetic injectables, lasers, radiofrequency and other energy-based modalities. MediZens Clinical director, Dr David Eccleston’s, areas of interest and experience are in Botulinum toxin therapy for facial rejuvenation and for the treatment of hyperhidrosis and migraine, facial fillers and facial volume restoration, collagen stimulation therapy, laser and radiofrequency facial rejuvenation and acne management. Topical antioxidant skin therapy and prescription skin rejuvenation is another area of interest. MediZen has been registered with the Care Quality Commission (CQC) since 2005 and have been independently audited and have met all standards required when we have been inspected through unannounced visits from the CQC In 2012 we were audited by the Medicines and Healthcare Products Regulatory Agency (MHRA) as we were the largest single investigative site in the UK for a phase III registration study on a novel lipolytic drug.

We have a state-of-the-art Dermatology suite, specialising in dermatological surgery, laser treatment of skin disease and cosmetic injectables and imaging systems including Canfield’s VISIA and 3D VECTRA Imaging System.

MediZen Ltd has been involved in conducting clinical trials since 2004, across a range of procedures and product types. Toxins, dermal fillers, injectable submental fat reduction, fibroblast implantation and LED Phototherapy Treatments.

Over the last few years MediZen has continued to develop its involvement in this area and as a consequence, now has a dedicated unit and resource for the administration, subject recruitment and implementation of clinical trial activity. As a result, the number and scope of trials we are involved with at any one time have increased, as has our reputation amongst some of the worlds largest Pharmaceutical companies, for being able to ensure that trial activity is conducted to the highest levels of compliance and accuracy. In addition, we have a proven history of submitting and getting trial protocols approved by local ethics committees.

About Dr David Eccleston

Dr David Eccleston

MediZen’s Clinical Director is Dr David Eccleston, who has 20 years experience in Medical Aesthetics.

He is also a Private GP in Sutton Coldfield, having also spent over 22 years as an NHS GP, and is in regular demand as a teacher and trainer in Medical Aesthetics.

David has trained and been involved in advisory panels with worldwide opinion leaders including Jean and Alastair Carruthers, Koenraad de Boulle, Zein Obagi and Mauricio De Maoi.  

Since 2006 he has been acknowledged as a Key Opinion Leader and Advisory Board Member for Allergan Inc and has presented and trained all over Europe and further afield, including Turkey, South Africa, Saudi Arabia, Jordan and the USA in various cosmetic techniques.

He has also run basic and advanced training courses around the world on the use of Botulinum Toxin, Hyaluronic Acid Fillers, Poly-L-Lactic acid (Sculptra), and ZO Medical products.

David has also appeared in and authored many magazine articles and taken part in television and radio interviews on the subject of non-surgical medical aesthetics.

He is also currently a medical adviser for the UK's largest aesthetic information website, and sits on advisory panels for a number of leading companies involved in producing products & treatments for the aesthetic market. 

Specific Trial Activity

Since 1992 Dr Eccleston has participated as a lead investigator in numerous clinical trials, at both pre-and post-marketing stages, covering many therapeutic areas. Most recently these include:

 1)      A comparative study of Dysport and Botox® in the treatment of glabellar frown lines – 2004

 2)      A study to assess effectiveness of a hand-held blue LED light device in the treatment of facial acne vulgaris – 2006

 3)      A double-blind placebo-controlled study on a novel botulinum toxin, Xeomin, in the treatment of crows feet – 2007

 4)      A study using human allogeneic fibroblast transplantation in the treatment of facial scars – 2008

 5)      A comparative study of Botox® and Xeomin in the treatment of glabellar folds – 2009

 6)      Assessment of a novel hyaluronic acid lip filler - 2010

 7)      Azzalure – botulinum toxin in crow’s feet study - 2011

 8)      Comparative study of an injectable submental fat reduction substance - 2011

 9)      A blinded comparative study of Restylane vs Juvederm Volbella in lip enhancement – 2012

10)     The use of Juvederm Voluma in facial recontouring – 2012

11)     Eyelash thickening and lengthening with Bimatoprost - 2013

12)     Evaluation of efficacy and compliance of a novel at-home blue light device for acne - 2013

13)     Evaluation of the safety and efficacy of treatment with Botox®  purified neurotoxin complex for subjects with facial forehead, glabella and lateral canthal lines for Allergan (the makers of Botox®) - 2014 - 2016

14)    Randomised blind and then open-label study to investigate the efficacy and safety of BTX-A-HAC NC in the treatment of moderate to severe glabellar line and assess the long-term efficacy and safety of the product following repeated treatments in this indication - 2015 - 2016 

15) Study regarding a temperature controlled methodology for the Indiba radio frequency device for skin tightening - 2016 - 2017

- If you would like to get in touch about our trials please contact:



The clinical trials team - Ian, Ruth and David